



## Nanoform to Expand its Presence to US Pharma Industry

2020-03-13

Nanoform, a nanotechnology-based pharmaceutical company based in Helsinki, Finland, has recently established Nanoform USA Inc., a fully-owned subsidiary in the US to have a strategic arm in a strategic market, aimed at introducing its award-winning nanonization™ technology to the American market.

[Nanoform](#), an innovative nanoparticle medicine enabling company, has established Nanoform [USA](#) Inc., a wholly owned subsidiary in the US. This is a natural progression for the company as it continues to increase the impact of its award-winning nanonization™ technology and expand its major pharma client base in the US.

The establishment of Nanoform [USA](#) Inc. follows the recent appointment of Sally Langa as Head of US Sales. Sally brings 30 years of valuable commercial experience in Pharma, having held senior positions at Catalent Pharma, Patheon and Halo Pharmaceutical. The expansion also coincides with increasing interest in Nanoform's technology within the US marketplace and the company's application for GMP status at its Finnish site, which is expected to further fuel demand for Nanoform's proprietary CESS® technology.



Prof. Edward Hæggström, Nanoform CEO, commented "We are tremendously excited to have officially established our presence in the US with a wholly owned subsidiary. This comes as a natural next step for our company as we continue to expand the reach of our nanonization™ technology."

Miguel Calado, Vice Chairman of the Nanoform Board, said, "I am thrilled we are establishing Nanoform [USA](#) Inc. With this strategic expansion, we now have a strong foundation on which to continue to grow our presence in the US."

Read the [original article](#) on Nanoform.